Research programme: recombinant protein therapeutics - APT Therapeutics
Alternative Names: APT 301; APT 302; APT 502Latest Information Update: 27 Dec 2019
At a glance
- Originator APT Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Platelet activating factor inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Myocardial infarction; Stroke
Highest Development Phases
- Discontinued Stroke; Thrombosis
Most Recent Events
- 16 Nov 2019 Discontinued - Preclinical for Stroke in USA (IV) as no longer mentioned in APT Therapeutics pipeline
- 16 Nov 2019 Discontinued - Preclinical for Thrombosis in USA (IV) as no longer mentioned in APT Therapeutics pipeline
- 04 Aug 2004 Compounds are available for licensing (http://www.apttherapeutics.com)